Menu Search
Equities

Deva Holding AS

DEVA.E:IST

Deva Holding AS

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TRY)64.35
  • Today's Change0.55 / 0.86%
  • Shares traded692.39k
  • 1 Year change-23.39%
  • Beta0.9590
Data delayed at least 15 minutes, as of Sep 20 2024 16:09 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in TRYIncome statement in TRYView more

Year on year Deva Holding AS grew revenues 30.04% from 8.71bn to 11.33bn while net income improved 297.79% from 851.06m to 3.39bn.
Gross margin40.49%
Net profit margin35.23%
Operating margin15.30%
Return on assets23.50%
Return on equity38.52%
Return on investment36.20%
More ▼

Cash flow in TRYView more

In 2023, Deva Holding AS increased its cash reserves by 53.02%, or 524.76m. The company earned 2.31bn from its operations for a Cash Flow Margin of 20.39%. In addition the company used 1.74bn on investing activities and also paid 180.92m in financing cash flows.
Cash flow per share25.61
Price/Cash flow per share2.51
Book value per share82.66
Tangible book value per share62.88
More ▼

Balance sheet in TRYView more

Deva Holding AS has a Debt to Total Capital ratio of 25.65%, a higher figure than the previous year's 12.70%.
Current ratio1.70
Quick ratio1.14
Total debt/total equity0.345
Total debt/total capital0.2565
More ▼

Growth rates in TRY

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 66.67% and 298.35%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
Div yield(5 year avg)0.52%
Div growth rate (5 year)--
Payout ratio (TTM)1.24%
EPS growth(5 years)90.11
EPS (TTM) vs
TTM 1 year ago		863.39
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.